GLP1R and diabetes mellitus: Increasingly, liver fat content is being recognized as another cardiovascular risk factor that often accompanies T2D, because 80% of patients with diabetes are thought to have concurrent fatty liver disease.85 There is early evidence that GLP-1 receptor agonists have the potential to improve hepatic health,28,79,80 as measured by hepatic enzyme concentrations, with implications for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, particularly in patients with T2D.